IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Amro Albanna, CEO of Aditxt, Inc.
August 02 2022 - 8:17AM
via InvestorWire – IBN (InvestorBrandNetwork), a multifaceted
communications organization engaged in connecting public companies
to the investment community, is pleased to announce the release of
the latest episode of The Bell2Bell Podcast as part of its
sustained effort to provide specialized content distribution via
widespread syndication channels.
The Bell2Bell Podcast delivers informative updates and exclusive
interviews with executives operating in fast-moving industries.
Bell2Bell’s latest podcast features Amro Albanna, Co-Founder,
Chairman and CEO of Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the
“Company”), a biotech innovation company.
Throughout the interview, Albanna provided an introduction to
Aditxt and discussed its business model.
“We are a biotech innovation company, and our focus is on immune
diseases. The reality is that immune diseases are caused either by
someone having too little immune response or too much immune
response,” Albanna said. “When you have too little immune response
and you’re dealing with COVID-19, we all understand the story, and
that applies to other viral diseases. Too much immunity is also not
a good thing. When you have too much immune response, you get into
the area of autoimmune diseases – multiple sclerosis, type I
diabetes, and psoriasis. These all happen when our immune system
begins to overreact and attack our own tissues and cells.”
“When you take this as a foundation, you really begin to
understand the power of Aditxt and what we’re doing. Number one, we
have a product and a technology platform called AditxtScore™ that
enables us to understand someone’s immune response and monitor that
immune response for a specific application. The second side of our
business is what we call immune modulation, which is the ability to
potentially retrain the immune system to make it recognize a
transplanted organ or our own tissues to potentially address
conditions like psoriasis and type I diabetes. That’s the
foundation of Aditxt. We are very well positioned to address some
of the most challenging immune-related diseases.”
“Aditxt is not a one-molecule company. That’s really important
right now, especially in markets like these, because it’s not a
binary outcome. Many young biotech companies either win big or lose
big, because they are betting on one technology or molecule. Our
business model is focused on commercializing multiple innovations
that focus on the monitoring and modulation of the immune system –
the diagnostic side as well as the therapeutic side. Our team is
really a reflection of that business model, and it’s the reason why
we’re here today. The DNA of our management team, starting with
myself, is focused on commercializing those innovations and
bringing promising science to the world.”
Join IBN’s Stuart Smith and Amro Albanna to learn more about the
company’s seasoned management team, as well as its recent
milestones and goals for the balance of 2022 and beyond.
To hear the episode and subscribe for future podcasts,
visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to
reinforce IBN’s commitment to the expansion of its robust network
of brands, client partners, followers and the growing IBN Podcast
Series. For more than 15 years, IBN has leveraged this commitment
to provide unparalleled distribution and corporate messaging
solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a
visual timeline, visit: https://IBN.fm/TimeLine
About Aditxt, Inc.
Aditxt is a biotech innovation company developing and
commercializing technologies focused on monitoring and
reprogramming the immune system. Aditxt’s immune monitoring
technologies are designed to provide a personalized immune profile.
Aditxt’s immune reprogramming technologies, currently preclinical,
are being developed to retrain the immune system to induce
tolerance to address rejection of transplanted organs, autoimmune
diseases and allergies. For more information, please visit
www.Aditxt.com and www.AditxtScore.com
About IBN
IBN consists of financial brands introduced to the investment
public over the course of 15+ years. With IBN, we have amassed a
collective audience of millions of social media followers. These
distinctive investor brands aim to fulfill the unique needs of a
growing base of client-partners. IBN will continue to expand our
branded network of highly influential properties, leveraging the
knowledge and energy of specialized teams of experts to serve our
increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its Investor Brand Platform,
IBN provides: (1) access to a network of wire solutions via
InvestorWire to reach all target markets, industries and
demographics in the most effective manner possible; (2) article and
editorial syndication to 5,000+ news outlets; (3) Press Release
Enhancement to ensure maximum impact; (4) full-scale distribution
to a growing social media audience; (5) a full array of corporate
communications solutions; and (6) total news coverage
solutions.
For more information, please visit
https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or re-published:
http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBN (InvestorBrandNetwork)Los Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024